(Q48770670)
Statements
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials (English)
Andrew Blauvelt
Kristian Reich
Stephen K Tyring
Rodney Sinclair
Kristine Nograles
Anish Mehta
Nicole Cichanowitz
Qing Li
Kenneth Liu
Carmen La Rosa